Araclon to begin Phase II trial of AD vaccine

This month, Araclon Biotech S.L. (Zaragoza, Spain) plans to begin enrollment in a Phase II trial of ABvac40 to treat patients with "very early stages" of Alzheimer's disease (AD). The placebo-controlled, European trial will establish dosage and evaluate safety and cognitive and molecular response in 120 patients. The company expects the trial to last 2 years.

ABvac40 is an active immunotherapy that targets the C-terminal fragment of beta amyloid 40...